Half of US physicians "prescribe placebos"

3 November 2008

A report in the British Medical Journal claims that "about half" of a random sample of 679 internists and rheumatologists across the USA have prescribed a drug to a patient with the intention of producing a placebo effect. According to the New York Times, the list of drugs being used to persuade "difficult patients" or those with conditions that are considered to be psychosomatic, included vitamins, antibiotics, painkillers and sedatives.

In some clinical trials for antidepressants, the beneficial effect of a placebo has been measured at well over 30%, in some cases not dissimilar to the active compound being tested. For other conditions where a reduction in anxiety or stress can produce results, such as pain or hypertension, sugar pills can produce significant improvements.

Ezekiel Emanuel, the chairman of the bioethics department at the National Institutes of Health, who contributed to the BMJ report, said: "everyone comes out happy: the doctor is happy, the patient is happy. But ethical challenges remain."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight